IDYA:IDEAYA Biosciences Inc Snapshot | Charting | News | Options
$38.27 NASDAQ 10:05a ET
April 24 '24 		IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Ph... PR Newswire
Last  Change Exchange
Market data is delayed by at least 15 minutes.
Markets Portfolio
    Symbol Lookup
    Latest Story
    IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
     PR Newswire

    -- Oral presentation atASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDT

    -- The abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ET

    IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that interim results from the investigator-sponsored Phase 2 trial evaluating darovasertib safety and efficacy as neoadjuvant/adjuvant treatment in uveal melanoma (UM) have been selected for an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.

    Full Story →

    Headline News
    IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
    6:00a ET April 22 '24 PR Newswire
    IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    6:00a ET April 5 '24 PR Newswire
    IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
    6:00a ET April 1 '24 PR Newswire
    More News →
    Day  3.96%Week  1.73%Month  9.97%More Charting →
    Today, 11:22a ET Thursday April 25 '24. Markets Open.
    Last $38.27
    Day change   3.96%$1.58
    Open $39.06
    Gap at open $0.79
    Previous close $39.85
    Trading volume 93,505
    10 Day avg vol. 650,420
    Shares out. 74.8Mil
    Market cap. $2.9Bil
    Trading activity Below Avg.
    Previous data from yesterday, April 24 '24.

    Historical Price Performance
    3 month   9.29% 
    6 month   49.67% 
    1 year   108% 
    2 year   293% 

    Earnings
    Previous 12m -$1.96
    Next 12m Estimate -$2.19
    P/E ratio 19.5x
    Revenue 23Mil

    Market data provided by News provided by


    This site is published in the United States for U.S. residents only. The services offered within this site are available exclusively through our U.S. Financial Advisors. Stifel Nicolaus Financial Advisors may only conduct business with residents of the state in which they are properly registered. The information on this website is not an offer to sell or a solicitation of an offer to buy, any security, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase or sale may not lawfully be made.
    Important Disclosures | Privacy Notice | HIPAA Policy | Use of Information Policy | Business Continuity | Canada Trade Matching Statement

    Stifel, Nicolaus & Co., Inc. Member NYSE, FINRA, and SIPC.
    Stifel Nicolaus Canada Inc., is a member of CIPF/FCPE and IIROC
    Copyright © 2024 All rights reserved.